Chronic Pressure Overload Induces Cardiac Hypertrophy and Fibrosis via Increases in SGLT1 and IL-18 Gene Expression in Mice
Open Access
- 1 September 2018
- journal article
- research article
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 59 (5), 1123-1133
- https://doi.org/10.1536/ihj.17-565
Abstract
Increased gene expression levels of sodium-glucose cotransporter 1 (SGLT1) are associated with hypertrophic and ischemic cardiomyopathy. However, it remains unclear whether chronic pressure overload increases SGLT1 expression, which in turn induces hypertrophic cardiomyopathy. We hypothesized that pressure overload could increase SGLT1 gene expression, leading to the development of hypertrophic cardiomyopathy. To create pressure overload-induced cardiomyopathy, transverse aortic constriction (TAC) was performed in SGLT1-deficient (SGLT1-/-) and wild-type (WT) mice. Six weeks after surgery, all mice were investigated. We observed a reduction of left ventricular fractional shortening and left ventricular dilatation in TAC-operated WT but not in TAC-operated SGLT1-/- mice. SGLT1, interleukin 18, connective tissue growth factor, and collagen type 1 gene expression levels were increased in TAC-operated WT mouse hearts compared with that of sham-operated WT mouse hearts. Moreover, heart/body weight ratio and ventricular interstitial fibrosis were increased in TAC-operated WT mice compared with that of sham-operated WT mice. Interestingly, these factors did not increase in TAC-operated SGLT1-/- mice compared with that of sham-operated WT and SGLT1-/- mice. Phenylephrine, an adrenergic α1 receptor agonist, caused cardiomyocyte hypertrophy in neonatal WT mouse hearts to a significantly larger extent than in neonatal SGLT1-/- mouse hearts. In conclusion, the results indicate that chronic pressure overload increases SGLT1 and IL-18 gene expressions, leading to the development of hypertrophic cardiomyopathy. These results make SGLT1 a potential candidate for the therapeutic target for hypertension-induced cardiomyopathy.Keywords
This publication has 38 references indexed in Scilit:
- Inducible Overexpression of GLUT1 Prevents Mitochondrial Dysfunction and Attenuates Structural Remodeling in Pressure Overload but Does Not Prevent Left Ventricular DysfunctionJournal of the American Heart Association, 2013
- Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin SecretionDiabetes, 2011
- SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathyJournal of Molecular and Cellular Cardiology, 2010
- Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-κB activationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- SGLT1 is a novel cardiac glucose transporter that is perturbed in disease statesCardiovascular Research, 2009
- Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overloadBiochemical and Biophysical Research Communications, 2007
- TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophyThe EMBO Journal, 2006
- Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failureJCI Insight, 2005
- CaMKII activates ASK1 and NF-κB to induce cardiomyocyte hypertrophyBiochemical and Biophysical Research Communications, 2005
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyThe New England Journal of Medicine, 1990